


## Data Sheet (Cat.No.T14493)

### Balapiravir

#### Chemical Properties

CAS No.:	690270-29-2
Formula:	C <sub>21</sub> H <sub>30</sub> N <sub>6</sub> O <sub>8</sub>
Molecular Weight:	494.5
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



#### Biological Description

Description	Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). IC <sub>50</sub> Value: Target: HCV Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Balapiravir (R1626) is the triisobutylate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration. Balapiravir(R-1626; R 1626; Ro 4588161) is useful for Anti HCV. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication.
Targets(IC <sub>50</sub> )	Others: None

#### Solubility Information

Solubility	DMSO: 100 mg/mL (202.22 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

#### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.022 mL	10.111 mL	20.222 mL
5 mM	0.404 mL	2.022 mL	4.044 mL
10 mM	0.202 mL	1.011 mL	2.022 mL
50 mM	0.04 mL	0.202 mL	0.404 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. *J Infect Dis.* 2013 May 1;207(9):1442-1450.
2. Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. *Ann Hepatol.* 2012 Jan-Feb;11(1):15-31.
3. Li F, et al. Chemical stability of 4'-azidocytidine and its prodrug balapiravir. *Drug Dev Ind Pharm.* 2010 Apr;36(4):413-20.
4. Kros PJ, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. *Hepatology.* 2008 Aug;48(2):385-97.
5. Roberts SK, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. *Hepatology.* 2008 Aug;48(2):398-406.
6. Chen YL, et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. *J Virol.* 2014 Feb;88(3):1740-1747.

**Inhibitors · Natural Compounds · Compound Libraries**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.**

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481